Discussion
schizophrenia, psychiatric, Psychotic symptoms
REMISSION
To our knowledge, this study is the first RCT to evaluate the therapeutic efficacy of MPGT in Chinese Han patients with schizophrenia. Consistent with our hypotheses, patients with schizophrenia randomized to MPGT achieved greater improvements in symptoms and reported lower plasma prolactin levels.Several studies have evaluated the effects of single test–guided or limited multigenetic-test–guided pharmacotherapy in schizophrenia.In our study, patients treated with MPGT responded better to antipsychotic medications but with relevantly lower doses, which can be seen in the greater reduction of PANSS score and higher response rate. We found that 93 of 113 pharmacogenomics-guided patients (82.3%) reached a 50% reduction of PANSS score at the end of week 6 and 71 of 113 (62.8%) achieved symptomatic remission at the end of week 12. Psychotic symptoms were reported to be significantly associated with patients’ psychosocial functioning, cognitive function, and quality of life,The genetic variants included in the multigenetic pharmacogenomic testing of our study involved drug metabolism, transporters, and receptors. A significant number of the loci detected were also related to CYPs. Most of the psychiatric drugs currently available are metabolized by CYPs, especially CYP1A2, CYP2C19, CYP2D6, and CYP3A4 isoforms.